UPCOMING – Zurich, Switzerland, February 26 to 27, 2025 – CIS BIOPHARMA, a Basel-based pioneer in precision oncology, is pleased to announce its participation in the 18th Annual European Life Sciences CEO Forum, taking place on February 26 to 27, 2025, at the Hilton Zurich Airport Hotel.

CIS BIOPHARMA will present its portfolio of next-generation antibody-drug conjugates and radiopharmaceuticals. Our innovative approach aims to significantly improve the lives of cancer patients worldwide by harnessing the power of antibodies and nanobodies, with programs advancing from discovery to clinical validation.

«The Sachs Forum provides an excellent platform to showcase our pioneering work in precision cancer therapies,» says Christoph Schäfer, CEO of CIS BIOPHARMA. «We are excited to engage with potential investors and partners to discuss our pipeline that targets antigens across various cancer types.»

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately owned, Basel-based oncology company that develops next-generation immuno-conjugates to address aggressive forms of tumors. The product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, selectively targeting tumor cells. CIS BIOPHARMA aims to help cancer patients live longer and better lives.